Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
The best HP laptops for every type of job and situation
Immortals of Aveum's Fantasy Firefights Prove Not All Shooters Need Guns
Apple Is Working on a Revamped iPad Pro
How tall is Pink Sparkles? Exploring Twitch streamer's height as compared to ex-boyfriend Asmongold
Amazon Music Prime Review
Cirque du Soleil Tycoon lands on Roblox
How much did Adin Ross spend on renovating brand new warehouse? Trolls say 'it's going to flop'
Mystery behind brightest explosion ever seen is finally solved